Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma

Brian C.-H. Chiu1*,†, Zhou Zhang2, Benjamin A. Derman3, Jason Karpus4, Liangzhi Luo4, Sheng Zhang4, Spencer S. Langerman1, Madina Sukhanova5, Parveen Bhatti6, Andrzej Jakubowiak3, Chuan He4,7 and Wei Zhang2*†

Abstract

Multiple myeloma (MM) and its precursors monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) are 2–3 times more common in African Americans (AA) than European Americans (EA). Although epigenetic changes are well recognized in the context of myeloma cell biology, the contribution of 5-hydroxymethylcytosines (5hmC) to racial disparities in MM is unknown. Using the 5hmC-Seal and next-generation sequencing, we profiled genome-wide 5hmC in circulating cell-free DNA (cfDNA) from 342 newly diagnosed patients with MM (n = 294), SMM (n = 18), and MGUS (n = 30). We compared differential 5hmC modifications between MM and its precursors among 227 EA and 115 AA patients. The captured 5hmC modifications in cfDNA were found to be enriched in B-cell and T-cell-derived histone modifications marking enhancers. Of the top 500 gene bodies with differential 5hmC levels between MM and SMM/MGUS, the majority (94.8%) were distinct between EA and AA and enriched with population-specific pathways, including amino acid metabolism in AA and mainly cancer-related signaling pathways in EA. These findings improved our understanding of the epigenetic contribution to racial disparities in MM and suggest epigenetic pathways that could be exploited as novel preventive strategies in high-risk populations.

Keywords: Multiple myeloma, 5-hydroxymethylcytosine, Racial disparity, Epigenetic modification

To the editor,

Multiple myeloma (MM) typically progresses from the precursor conditions of monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM). Compared with European Americans (EA), African Americans (AA) are 2–3 times more likely to be diagnosed with MM. Genetic susceptibility, socioeconomic factors, and obesity do not fully explain the excess risk in AA. Clinical variations of MM between EA and AA suggest a biological cause of racial/ethnic
disparities [1]. Although the importance of epigenetics to MM is recognized, previous studies have not investigated genome-wide 5-hydroxymethylcytosines (5hmC), a cytosine modification with a distinct genomic distribution and regulatory role from the more-investigated 5-methylcytosines (5mC) [2]. Reduced global 5hmC levels have been found in MM [3] and MM-specific hydroxymethylome is associated with cell proliferation and prognosis [4]. To improve understanding of the role of 5hmC in disparities in MM, we conducted a genome-wide 5hmC profiling using the 5hmC-Seq and the next-generation sequencing in circulating cell-free DNA (cfDNA) samples from 227 EA and 115 AA patients with newly diagnosed MM, SMM, and MGUS prospectively enrolled at the University of Chicago Medical Center between 2010 and 2017. (Additional file 1: Table S1; Additional file 2).

Overall, the captured 5hmC modifications in cfDNA were more abundant in gene bodies and depleted at the promoter regions (Fig. 1A). Using the Roadmap Epigenomics Project annotations as reference, we found that patient-derived 5hmC profiles were enriched in B-cell and T-cell-derived enhancer marks: H3K4me1 and H3K27ac (Fig. 1B).

Comparing MM and its precursors (MGUS + SMM), we identified 63 differential gene bodies at 5% FDR (false discovery rate) (Fig. 1C; Additional file 3: Table S2) after controlling for sex, age, and race/ethnicity. The KEGG pathway analysis identified several metabolism-related pathways (e.g., citrate cycle) that have been implicated in myeloma cell growth and proliferation as well as the pathogenesis of MM (Fig. 1D) (Additional file 3: Table S3).

Next, we identified 259 differential gene bodies (5% FDR) between EA and AA patients with MM (Additional file 4: Fig. S1; Additional file 3: Table S4), of which 183 showed higher 5hmC modification levels in AA patients. Of note, LIN28A is one of the most frequently mutated genes reported in MM [5], while KANSL1, LRRC37A3, and ARL17B are in a region (chr17q21) with a segmental duplication that is primarily found in European descents [6]. We identified several metabolism related KEGG pathways (Additional file 3: Table S5). The co-expression network analysis revealed three modules showing different direction of enrichment between AA and EA (Fig. 1E). Furthermore, the protein–protein interaction network analysis identified several relevant hub genes (Fig. 1F–H). For example, FHL2 (Module 1) has been found to regulate hematopoietic stem cell functions [7] and the production of IL6 [8], a cytokine critical to myeloma cell proliferation. Low expression of FHL2 has also been associated with development of IgM myeloma [9].

We then compared MM and its precursors in EA and AA patients separately. We identified 36 and 4 differential gene bodies (5% FDR) in EA and AA patients, respectively (Fig. 2A, B; Additional file 3: Table S6-7). Simulation analyses showed that the number of shared differential genes between EA and AA reached a peak around the 500th rank (Fig. 2C). The majority (94.8%) of the top 500 differential gene bodies were distinct between EA and AA (Fig. 2D), suggesting that although there is mechanistic commonality of myelomagenesis, racial/ethnic heterogeneity exists. The pathway analysis of the top 500 differential gene bodies showed population-specific KEGG pathways (Fig. 2E; Additional file 3: Table S8), including various cancer-related signaling pathways in EA patients, but primarily metabolism-related pathways in AA patients. For example, PIK3CA, which was enriched in several cancer-related signaling pathways in EA patients only, is important for constitutive Akt activity in MM cells and the blockade of PIK3CA induces cell death [10]. In contrast, several ALDH family genes were enriched in metabolism-related pathways in AA patients only. Increased expression of ALDH1 in MM has been identified as a marker of tumor-initiating cells and is associated with chromosomal instability [11]. Specific transcriptional networks related to metabolisms have also been found to contribute to plasma cell growth and proliferation [12].

**Fig. 1** Genome-wide profiling of 5hmC from cfDNA derived from EA and AA patients with MM and its precursors. Genome-wide 5hmC was profiled in patient-derived plasma cfDNA samples using the 5hmC-Seq and the next-generation sequencing. The 5hmC-Seq data summarized for gene bodies were the primary targets for differential analysis between MM and its precursors (MGUS + SMM, i.e., MGUS and SMM combined) in all samples, using multivariable logistic regression models, controlling for age, sex, and self-reported race/population. In addition, we performed differential analysis between EA and AA patients with MM only. A The captured 5hmC-Seq reads in cfDNA are more abundant in gene bodies relative to the flanking regions and depleted at the promoter regions, based on the GENCODE annotations (hg19). TSS: transcription start site; TES: transcription end site. B The captured 5hmC-Seq reads are enriched in histone modifications marking enhancers (H3K4me1 and H3K27ac) derived from B-cells and T-cells compared with other tissue types. The annotations for H3K4me1 and H3K27ac were obtained from the Roadmap Epigenomics Project. The standard error is shown as the error bar. C The heatmap shows the top 63 differential gene bodies between MM and its precursors in the combined EA and AA patients. D Shown are the enriched KEGG pathways among the top 500 differential gene bodies between MM and its precursors in the combined EA and AA samples. The X-axis represents the ratio between the number of differential genes and the total genes in a given pathway. E The co-expression Network Enrichment Analysis was performed for differential gene bodies between EA and AA to provide further biological insights. Specifically, three modules (Module 1: 254 genes; Module 2: 156 genes; and Module 3: 75 genes) are shown from the modular gene co-expression analysis using the top 500 differential gene bodies between EA and AA patients with MM as the input. NES: normalized enrichment score. F–H Shown are the protein–protein interaction networks constructed for the co-expression and/or interaction modules identified from differential gene bodies between EA and AA patients with MM.
In conclusion, we identified population-specific 5hmC signatures and pathways that improved our understanding of the epigenetic mechanisms underlying the disparities in MM. These findings could be exploited for novel preventive strategies in high-risk populations in the future.
Fig. 2  Differential analysis reflects population-specific 5hmC signatures and pathways between MM and its precursors. The 5hmC-Seal profiles summarized for gene bodies were compared between MM and its precursors (MGUS + SMM, i.e., MGUS and SMM combined) in AA and EA samples, separately, using multivariable logistic regression models, controlling for age and sex. A The heat map shows the top 36 differential genes between MM and its precursors in EA patients. B The heat map shows the top 36 differential genes between MM and its precursors in AA patients. C Shown is the number of shared differential gene bodies between MM and its precursors in individual populations (AA vs. EA), compared with the null distribution. The blue line represents the mean of a null distribution generated by permutation (N=10,000). The red line represents the observed number of shared differential gene bodies. D The Venn Diagram shows the number of shared gene bodies (top 500) between MM and its precursors in EA, AA, and the combined samples. E Shown are the enriched population-specific KEGG pathways for the top 500 differential gene bodies between MM and its precursors in EA and AA.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13045-022-01327-y.

Additional file 1: Table S1. Characteristics of study subjects, UChicago Multiple Myeloma Epidemiology Study, 2010-2017.  

Additional file 2: Materials and Methods.  

Additional file 3: Table S2. Top 500 differentially modified gene bodies between MM and its precursors in the combined samples. Table S3. Enriched KEGG pathways among differentially modified genes between MM and its precursors in the combined samples. Table S4. Top 500 differentially modified gene bodies between AA and EA patients with MM. Table S5. Enriched KEGG pathways among differentially modified genes between AA and EA patients with MM. Table S6. Top 500 differentially modified gene bodies between MM and its precursors in EA patients. Table S7. Top 500 differentially modified gene bodies between MM and its precursors in different populations.  

Additional file 4: Fig. S1. Supplementary results for the differential analysis between AA and EA patients with MM. Differential analysis was performed between AA and EA patients with MM for each gene body (5hmC modification levels, i.e., the normalized 5hmC-Seal read counts), using multivariable logistic regression models, controlling for age and sex. The heat map shows the 259 differential gene bodies at 5% FDR between AA and EA patients with MM.  

Acknowledgements  
The authors would like to thank the Epidemiology and Research Recruitment Core of the University of Chicago Comprehensive Cancer Center for coordinating the subject recruitment and sample collection. C.H. is a Howard Hughes Medical Institute Investigator.  

Author contributions  
BC and W.Z. designed the study and provided oversight; ZZ conducted the bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results; CH supervised the 5hmC-Seal bioinformatic processing and statistical analysis, BAD and AJ provided clinical advice and helped interpret the results. BC and W.Z. designed the study and provided oversight; ZZ conducted the study and provided oversight; ZZ conducted the study and provided oversight; ZZ conducted the study and provided oversight; ZZ conducted the study and provided oversight; ZZ conducted the study and provided oversight; ZZ conducted the study and provided oversight; ZZ conducted the study and provided oversight; ZZ conducted the study and provided oversight; ZZ conducted the study and provided oversight; ZZ conducted the study and provided oversight.  

Funding  
This work was supported in part by National Institutes of Health grants R01CA223662 (B.C. and W.Z.) and R33CA269100 (B.C. and W.Z.).  

Availability of data and materials  
The raw and processed ShmC-Seal data in the current study are available from the corresponding authors on reasonable request.  

Declarations  
This study was approved by the University of Chicago Institutional Review Board (Approval No. 10-1788 and 14-0482).  

Ethics approval and consent to participate  
This study was approved by the University of Chicago Institutional Review Board (Approval No. 10-1788 and 14-0482).  

Consent for publication  
Not applicable.  

Competing interests  
C.H. and W.Z. were shareholders of Epican Technology, Ltd, which held a license of the ShmC-Seal technique from the University of Chicago for clinical applications. C.H. is the founder of Accent Therapeutics, Inc. and a member of its scientific advisory board. The remaining authors declare no conflict of interests.  

Author details  
1Department of Public Health Sciences, The University of Chicago, Chicago, IL 60637, USA.  
2Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.  
3Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.  
4Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.  
5Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.  
6Department of Cancer Control Research, BC Cancer Research Institute, Vancouver, BC V5Z1L3 0611, Canada.  
7Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, and Howard Hughes Medical Institute, The University of Chicago, Chicago, IL 60637, USA.  

Received: 26 June 2022  Accepted: 5 August 2022  
Published online: 16 August 2022  

References  
1. Aliawadhi S, Jacobus S, Sexton R, Steward AK, Dispensieri A, Hussein MA, et al. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J. 2018;8(7):67.  
2. Cui XL, Nie J, Ku J, Dougherty U, West-Szymanski DC, Collin F, et al. A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation. Nat Commun. 2020;11(1):1616.  
3. Margalit S, Avraham S, Shahal T, Michaeli Y, Gilat N, Magod P, et al. 5-Hydroxymethylcytosine as a clinical biomarker: fluorescence-based assay for high-throughput epigenetic quantification in human tissues. Int J Cancer. 2020;146(1):115–22.  
4. Chatonnet F, Pignarre A, Serandour AA, Caron G, Avner S, Robert N, et al. The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation. Haematologica. 2020;105(3):774–83.  
5. Segalla S, Pivetti S, Todoroki K, Chudzik MA, Giuliani EC, Lazzaro F, et al. The ribonuclease D53 promotes let-7 miRNA maturation by degrading the pluri potency factor LIN28B miRNA. Nucleic Acids Res. 2015;43(10):5182–93.  
6. Steinberg KM, Antonacci F, Sudmant PH, Kidd JM, Campbell CD, Vives L, et al. Structural diversity and African origin of the 17q21.31 inversion polymorphism. Nat Genet. 2012;44(8):872–80.  
7. Hou Y, Wang X, Li L, Fan R, Chen J, Zhu T, et al. FHL2 regulates hematopoietic stem cell functions under stress conditions. Leukemia. 2015;29(3):615–24.  
8. Wong CH, Mak GW, Li MS, Tsui SK. The LIM-only protein FHL2 regulates interleukin-6 expression through p38 MAPK mediated NF-kappaB pathway in muscle cells. Cytokine. 2012;59(2):286–93.  
9. Chehal A, Taher A, Shamseddine A. IgM myeloma and Waldenstrom’s macroglobulinemia: a distinct clinical feature, histology, immunophenotype, and chromosomal abnormality. Clin Lab Haematol. 2003;25(3):187–90.  
10. Hoffmann C, Stuhmer T, Schmiedl N, Wetzker R, Mottok A, Rosenwald A, et al. PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform. Br J Haematol. 2014;166(4):529–39.  
11. Zhou W, Yang Y, Gu Z, Wang H, Xia J, Wu X, et al. ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia. 2014;28(5):1155–8.  
12. Kasambara A, Herviou L, Ovejeiro S, Jourdan M, Thibaut C, Vikova V, et al. RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators. Leukemia. 2021;35(5):1451–62.  

Publisher’s Note  
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.